•  
  •  
 

Abstract

Background: The term “skin booster” is commonly referred to in dermatology. These products may comprise several components, including exosomes, secretomes, chitosan, polydeoxyribonucleotide, platelet-rich plasma, and hyaluronic acid. In today’s world, the use of such products is not confined to aesthetic purposes; they are also used to treat several other skin conditions. This review paper highlights the role of “skin booster" components for different skin disorders based on their in vitro, in vivo, and clinical studies.

Discussion: “Skin boosters” are bioactive agents typically administered into the dermal layer. Understanding the mechanisms of each component is important because their applications extend beyond skin revitalization to include other forms of therapeutic revitalization. These findings suggest the possibility of a new treatment strategy. Currently, emerging evidence suggests that “skin boosters” have applications beyond aesthetics, particularly as an adjuvant therapy to improve skin integrity, reduce inflammation, and enhance tissue regeneration.

Conclusion: Research on the components of “skin boosters" may be used to treat various skin diseases. However, their use should remain adjunctive, as current evidence is insufficient to support first-line treatment. Clinical trials, appropriate patient selection, and application guidelines must be established to enhance the scientific validity and rationale for this treatment modality.

References

  1. Yi HK, Winayanuwattikun W, Kim SY, et al. Skin boosters: Definitions and varied classifications. Skin Res Technol. 2024;30(3):1–13.
  2. Oh SM, Lee Y, Lee JH, Oh M. Investigating the mechanisms of intradermal injection for easier "Skin booster" treatment:  A fluid mechanics approach to determine optimal delivery method. Plast Reconstr Surg Glob Open. 2024;12(4):1–7.
  3. Thakur A, Shah D, Rai D, et al. Therapeutic values of exosomes in cosmetics, skincare, tissue regeneration, and dermatological diseases. Cosmetics. 2023;10(2):1–14.
  4. Yu H, Feng H, Zeng H, et al. Exosomes: The emerging mechanisms and potential clinical applications in dermatology. Int J Biol Sci. 2024;20(5):1778–95.
  5. Kwon Y, Choi Y, Kim M, Jeong MS, Jung HS, Jeoung D. HDAC6 and CXCL13 mediate atopic dermatitis by regulating cellular interactions and expression levels of miR-9 and SIRT1. Front Pharmacol. 2021;12:1–17.
  6. Shin KO, Ha DH, Kim JO, et al. Exosomes from human adipose tissue-derived mesenchymal stem cells promote epidermal barrier repair by inducing de novo synthesis of ceramides in atopic dermatitis. Cells. 2020;9(3):1–23.
  7. Shi C, Pei S, Ding Y, et al. Exosomes with overexpressed miR-147a suppress angiogenesis and inflammatory injury in an experimental model of atopic dermatitis. Sci Rep. 2023;13:1–14.
  8. Shin HT, Lee SH, Yoon HS, et al. Long-term efficacy and safety of intravenous injection of clonal mesenchymal stem cells derived from bone marrow in five adults with moderate to severe atopic dermatitis. J Dermatol. 2021;48(8):1236–42.
  9. Wang M, Zhao Y, Zhang Q. Human mesenchymal stem cell-derived exosomes accelerate wound healing of mice eczema. J Dermatolog Treat. 2022;33(3):1401–5.
  10. Zhu T, Sun J, Ma L, Tian J. Plasma exosomes from children with atopic dermatitis may promote apoptosis of keratinocytes and secretion of inflammatory factors in vitro. Clin Cosmet Investig Dermatol. 2022;15:1909–17.
  11. Roh YJ, Choi YH, Shin SH, et al. Adipose tissue-derived exosomes alleviate particulate matter-induced inflammatory response and skin barrier damage in the atopic dermatitis-like triple-cell model. PLoS One. 2024;19(1):1–12.
  12. Huang R, Jia B, Su D, et al. Plant exosomes fused with engineered mesenchymal stem cell-derived nanovesicles for synergistic therapy of autoimmune skin disorders. J Extracell Vesicles. 2023;12(10):1–23.
  13. Yoon J, Lee SK, Park A, et al. Exosome from IFN-γ-primed induced pluripotent stem cell-derived mesenchymal stem cells improved skin inflammation and barrier function. Int J Mol Sci. 2023;24(14):1–15.
  14. Damayanti RH, Rusdiana T, Wathoni N. Mesenchymal stem cells secretome for dermatology application: A review. Clin Cosmet Investig Dermatol. 2021;14:1401–12.
  15. Amirthalingam M, Bhat S, Dighe P, Seetharam R. Human mesenchymal stromal cells-derived conditioned medium based formulation for advanced skin care: In vitro and in vivo evaluation. J Stem Cell Res Dev. 2019;5:1–8.
  16. Kim HJ, Jung MS, Hur YK, Jung AH. A study on the clinical effectiveness of cosmetics containing human stem cell conditioned media. Biomed Dermatol. 2020;4:1–11.
  17. Yusharyahya SN, Japranata VV, Sitohang IBS, et al. A comparative study on adipose-derived mesenchymal stem cells secretome delivery using microneedling and fractional CO2 laser for facial skin rejuvenation. Clin Cosmet Investig Dermatol. 2023;16:387–95.
  18. Legiawati L, Suseono LS, Sitohang IBS, et al. Combination of adipose-derived stem cell conditioned media and minoxidil for hair regrowth in male androgenetic alopecia: A randomized, double-blind clinical trial. Stem Cell Res Ther. 2023;14(1):1–13.
  19. Xia Y, Wang D, Liu D, et al. Applications of chitosan and its derivatives in skin and soft tissue diseases. Front Bioeng Biotechnol. 2022;10:1–13.
  20. Chuah LH, Loo HL, Goh CF, Fu JY, Ng SF. Chitosan-based drug delivery systems for skin atopic dermatitis: Recent advancements and patent trends. Drug Deliv Transl Res. 2023;13(5):1436–55.
  21. Guzmán E, Ortega F, Rubio RG. Chitosan: A promising multifunctional cosmetic ingredient for skin and hair care. Cosmetics. 2022;9(5):1–15.
  22. Squadrito F, Bitto A, Irrera N, et al. Pharmacological activity and clinical use of PDRN. Front Pharmacol. 2017;8:1–7.
  23. Pratama AM, Muharram AR. Salmon DNA combination for hypertrophic scar treatment with diabetes mellitus type 2: A case report. Int J Med Sci Clin Res. 2022;2(8):846–9.
  24. Khan A, Wang G, Zhou F, et al. Polydeoxyribonucleotide: A promising skin anti-aging agent. Chin J Plast Reconstr Surg. 2022;4:187–93.
  25. Manole CG, Soare C, Ceafalan LC, Voiculescu VM. Platelet-rich plasma in dermatology: New insights on the cellular mechanism of skin repair and regeneration. Life (Basel). 2024;14(1):1–36.
  26. Legiawati L, Yusharyahya SN, Bernadette I, et al. Comparing single-spin versus double-spin platelet-rich plasma (PRP) centrifugation methods on thrombocyte count and clinical improvement of androgenetic alopecia: A preliminary, randomized, double-blind clinical trial. J Clin Aesthet Dermatol. 2023;16(12):39–44.
  27. Emer J. Platelet-rich plasma (PRP): Current applications in dermatology. Skin Therapy Lett. 2019;24(5):1–6.
  28. Suthar M, Gupta S, Bukhari S, Ponemone V. Treatment of chronic non-healing ulcers using autologous platelet-rich plasma: A case series. J Biomed Sci. 2017;24(1):1–10.
  29. Keen MA. Hyaluronic acid in dermatology. Skinmed. 2017;15(6):441–8.
  30. Bukhari SNA, Roswandi NL, Waqas M, et al. Hyaluronic acid, a promising skin rejuvenating biomedicine: A review of recent updates and pre-clinical and clinical investigations on cosmetic and nutricosmetic effects. Int J Biol Macromol. 2018;120(Pt B):1682–95.
  31. Parmar SS, Modi A. An approach to treatment modalities of keloids: A comparative study. Int J Res Dermatol. 2022;8(1):45–9.
  32. Halachmi S, Amitai DB, Lapidoth M. Treatment of acne scars with hyaluronic acid: An improved approach. J Drugs Dermatol. 2013;12(7):e121–3.
  33. Muhammad P, Novianto E, Setyorini M, et al. Effectiveness of topical hyaluronic acid of different molecular weights in xerosis cutis treatment in elderly: A double-blind, randomized controlled trial. Arch Dermatol Res. 2024;316(6):1–6.
  34. Konstantinova VA, Olisova OY, Gladko VV, Burova EP. Vitiligo – new treatment approach. Clin Cosmet Investig Dermatol. 2019;12:911–17.
  35. Lee YH, Park HK, Auh QS, et al. Emerging potential of exosomes in regenerative medicine for temporomandibular joint osteoarthritis. Int J Mol Sci. 2020;21(4):1–21.
  36. de la Torre P, Pérez-Lorenzo MJ, Alcázar-Garrido A, Flores AI. Cell-based nanoparticles delivery systems for targeted cancer therapy: Lessons from anti-angiogenesis treatments. Molecules. 2020;25(3):1–23.
  37. Dal'Forno-Dini T, Birck MS, Rocha M, Bagatin E. Exploring the reality of exosomes in dermatology. An Bras Dermatol. 2025;100(1):121–30.
  38. Sumarwoto T, Suroto H, Mahyudin F, et al. Role of adipose mesenchymal stem cells and secretome in peripheral nerve regeneration. Ann Med Surg (Lond). 2021;67:1–10.
  39. Sipos F, Műzes G. Disagreements in the therapeutic use of mesenchymal stem cell-derived secretome. World J Stem Cells. 2022;14(6):365–71.
  40. Garg U, Chauhan S, Nagaich U, Jain N. Current advances in chitosan nanoparticles based on drug delivery and targeting. Adv Pharm Bull. 2019;9(2):195–204.
  41. Kale P, Shrivastava S, Pundkar A, Balusani P. Harnessing healing power: A comprehensive review on platelet-rich plasma in compound fracture care. Cureus. 2024;16(1):1–8.
  42. Juncan AM, Moisă DG, Santini A, et al. Advantages of hyaluronic acid and its combination with other bioactive ingredients in cosmeceuticals. Molecules. 2021;26(15):1–43.

Download

Share

COinS